14 April 2011 
EMA/CHMP/304146/2011  
Committee for medicinal products for human use (CHMP) 
Summary of opinion1 (post authorisation) 
Pradaxa 
dabigatran etexilate mesilate 
On  14  April  2011  the  Committee  for  Medicinal  Products  for  Human  Use  (CHMP)  adopted  a  positive 
opinion  recommending  a  variation  to  the  terms  of  the  marketing  authorisation  for  the  medicinal 
product Pradaxa. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim 
International  GmbH.  They  may  request  a  re-examination  of  the  CHMP  opinion,  provided  that  they 
notify  the  European  Medicines  Agency  in  writing  of  their  intention  within  15  days  of  receipt  of  the 
opinion. 
The CHMP adopted a new indication as follows: 
“Prevention  of  stroke  and  systemic  embolism  in  adult  patients  with  nonvalvular  atrial 
fibrillation with one or more of the following risk factors: 
Previous stroke, transient ischemic attack, or systemic embolism (SEE) 
•  Left ventricular ejection fraction < 40 % 
•  Symptomatic heart failure, ≥ New York Heart Association (NYHA) Class 2 
•  Age ≥ 75 years 
•  Age ≥ 65 years associated with one of the following: diabetes mellitus, coronary artery 
disease, or hypertension” 
The CHMP adopted a change to a contraindication as follows: 
“Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole and tacrolimus 
(see section 4.5)”. 
Detailed  conditions  for  the  use  of  this  product  will  be  described  in  the  updated  summary  of  product 
characteristics  (SmPC),  which  will  be  published  in  the  revised  European  public  assessment  report 
(EPAR),  and  will  be  available  in  all  official  European  Union  languages  after  the  variation  to  the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7<sector fax> 
E-mail  info@ema.europa.eu  Website  www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
                                               
 
For information, the full indications for Pradaxa will be as follows2: 
For 75 mg strength 
Primary  prevention  of  venous  thromboembolic  events  in  adult  patients  who  have  undergone  elective 
total hip replacement surgery or total knee replacement surgery. 
For 110 and 150 mg strengths 
Primary  prevention  of  venous  thromboembolic  events  in  adult  patients  who  have  undergone  elective 
total hip replacement surgery or total knee replacement surgery. 
Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial 
fibrillation with one or more of the following risk factors: 
•  Previous stroke, transient ischemic attack, or systemic embolism (SEE) 
•  Left ventricular ejection fraction < 40 % 
•  Symptomatic heart failure, ≥ New York Heart Association (NYHA) Class 2 
•  Age ≥ 75 years 
•  Age ≥ 65 years associated with one of the following: diabetes mellitus, coronary artery 
disease, or hypertension 
For information, the full contraindication(s) for Pradaxa will be as follows3: 
•  Hypersensitivity to the active substance or to any of the excipients 
• 
Patients with severe renal impairment (CrCL < 30 ml/min) 
•  Active clinically significant bleeding 
•  Organic lesion at risk of bleeding 
•  Spontaneous or pharmacological impairment of haemostasis 
•  Hepatic impairment or liver disease expected to have any impact on survival 
•  Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole and tacrolimus 
(see section 4.5) 
2 The text in bold represents the new or the amended indication. 
3 The text in bold represents the new or the amended contraindication. 
Pradaxa  
EMA/304146/2011  
Page 2/2
 
 
 
                                               
 
 
